Avelumab - Merck KGaA

Drug Profile

Avelumab - Merck KGaA

Alternative Names: Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck KGaA; BAVENCIO; MSB-0010718C; PF-06834635

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer AIO Studien gGmbH; Dana-Farber Cancer Institute; Debiopharm; Effector Therapeutics; EMD Serono; Fred Hutchinson Cancer Research Center; Hospices Civils de Lyon; Johannes Gutenberg-University Mainz; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); Pfizer; Syndax Pharmaceuticals; University of Birmingham; University of California, San Diego; Vaccinex; Vanderbilt-Ingram Cancer Center; Verastem; Washington University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Programmed cell death-1 ligand-1inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma
  • Registered Urogenital cancer
  • Phase III Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Liposarcoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase II Endometrial cancer; Gestational trophoblastic disease; Glioblastoma; Intestinal cancer; Nasopharyngeal cancer; Neuroendocrine tumours; Osteosarcoma; Peripheral T-cell lymphoma; Recurrent respiratory papillomatosis; Solid tumours; Thymoma
  • Phase I/II Fallopian tube cancer; Leiomyosarcoma; Lymphoma; Peritoneal cancer
  • Phase I Acute myeloid leukaemia; Hepatocellular carcinoma; Hodgkin's disease; Meningioma

Most Recent Events

  • 21 Mar 2018 Pfizer plans the Javelin Medley VEGF phase II trial for Non-Small Cell Lung Cancer and Urogenital cancer (Late-stage disease, Second-line therapy or greater) in April 2018 , (NCT03472560)
  • 07 Mar 2018 Phase-I/II clinical trials in Lymphoma (In adolescents, In children, In infants, In neonates, Second-line therapy or greater) in USA, Germany, Belgium (IV) (NCT03451825) (EudraCT2017-002985-28)
  • 07 Mar 2018 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, In adolescents, In children, In infants, In neonates) in Belgium, Germany, USA (IV) (NCT03451825) (EudraCT2017-002985-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top